LifeStance Health Group's higher P/S ratio is likely due to anticipation of continued robust revenue performance. Shareholders seem at ease with this P/S, confident in the company's future revenue prospects and expecting it to outperform its industry.
LifeStance Health股票讨论
• $艾斯本科技(AZPN.US)$ : Loop Capital 升级为持仓买入-PT $175
• $CSX运输(CSX.US)$ : 加拿大皇家银行资本从行业表现上调至跑赢大盘-PT 39美元（从37美元起）
• $艺康集团(ECL.US)$ : 爱德华·琼斯升级为持仓买入
• $Fortive(FTV.US)$ : 阿格斯升级为持仓买入-PT $68
• $Health Catalyst(HCAT.US)$ : Jefferies 升级为持仓买入-PT 28 美元（31 美元起）
• $亨廷顿英格尔斯工业(HII.US)$ : 垂直研究升级...
暂无评论